Keros Therapeutics corporate presentation highlights Phase 2 data and cash runway into 2028

Keros Therapeutics, Inc.

Phase 2 KER-050 in lower-risk MDS: 45% RBC transfusion independence at 24 weeks (ASH Dec 2025).
Phase 2 KER-012 in PAH met primary endpoint: 35m improvement in 6-min walk distance at 24 weeks.
Cash, equivalents and short-term investments of $367.4M as of Sep 30, 2025, funding operations into 2028.
Upcoming milestones: KER-050 higher-risk MDS data mid-2026; KER-012 HFpEF trial start H1 2026; KER-065 Phase 1 data H1 2026.
No new financing, leadership changes, or material agreements disclosed in the update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.